Search

Your search keyword '"T. Mizukami"' showing total 687 results

Search Constraints

Start Over You searched for: Author "T. Mizukami" Remove constraint Author: "T. Mizukami"
687 results on '"T. Mizukami"'

Search Results

151. Influence of Pathophysiologic Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes.

153. Advancements and future perspectives in coronary angiography-derived fractional flow reserve.

154. The Effect of Thickened Water on Ciprofloxacin Pharmacokinetics: A Comparative Study in Adult Males.

155. Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.

156. Highly homologous simian T-cell leukemia virus type 1 genome in Japanese macaques: a large cohort study.

157. Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients.

158. Remission With Radiation Therapy in Primary Tongue Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Report.

159. Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia.

160. Stent sizing by coronary CT angiography compared with optical coherence tomography.

161. Genetic Analysis of SCN11A , SCN10A , and SCN9A in Familial Episodic Pain Syndrome (FEPS) in Japan and Proposal of Clinical Diagnostic Criteria.

162. Carbon-ion radiotherapy for inoperable upper tract ureteral cancer.

163. Accelerated Fractionated Radiation Therapy for Localized Glottic Carcinoma.

164. Impact of vessel volume on thermodilution measurements in patients with coronary microvascular dysfunction.

165. The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling.

166. A Systematic Approach to the Evaluation of the Coronary Microcirculation Using Bolus Thermodilution: CATH CMD.

167. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).

168. Impact of coronary CT image quality on the accuracy of the FFR CT Planner.

169. Advanced CT Imaging for the Assessment of Calcific Coronary Artery Disease and PCI Planning.

170. Influence of intracoronary hemodynamic forces on atherosclerotic plaque phenotypes.

171. Intravascular Imaging Findings After PCI in Patients With Focal and Diffuse Coronary Artery Disease.

172. The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants.

173. Non-conditioned cord blood transplantation for infection control in athymic CHARGE syndrome.

174. Measuring Absolute Coronary Flow and Microvascular Resistance by Thermodilution: JACC Review Topic of the Week.

175. Report for the Eighth Asian National Control Laboratory Network meeting in 2023: Self-sufficiency strategy of plasma-derived medicinal products and regulatory harmonisation.

176. Blood Flow Energy Identifies Coronary Lesions Culprit of Future Myocardial Infarction.

177. Assessing the Impact of Prolonged Averaging of Coronary Continuous Thermodilution Traces.

178. Exercise-induced vasospastic angina diagnosed with a hand grip test in the catheterization laboratory: a case report.

179. Safety of Oral Food Challenge for Individuals with Low Egg White and Ovomucoid-Specific IgE Antibodies.

180. Identification of Chemicals That Abrogate Folate-Dependent Inhibition of Starch Accumulation in Non-Photosynthetic Plastids of Arabidopsis.

181. Acceleration of Protein Degradation by 20S Proteasome-Binding Peptides Generated by In Vitro Artificial Evolution.

182. Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD.

183. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.

184. Continuous vs Bolus Thermodilution to Assess Microvascular Resistance Reserve.

185. Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells.

186. Coronary Atherosclerosis Phenotypes in Focal and Diffuse Disease.

187. Rationale and design of the pullback pressure gradient (PPG) global registry.

188. Association between Eicosapentaenoic Acid to Arachidonic Acid Ratio and Characteristics of Plaque Rupture.

189. Prognostic Impact of Renal Function on 5-Year Outcomes After Fractional Flow Reserve-Guided Deferral of Revascularization.

190. Diagnosis and Prognostic Value of the Underlying Cause of Acute Coronary Syndrome in Optical Coherence Tomography-Guided Emergency Percutaneous Coronary Intervention.

191. Impact of Post-PCI FFR Stratified by Coronary Artery.

192. Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.

193. Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile.

194. Optical Coherence Tomography-Guided Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Rationale and Design of the ATLAS-OCT Study.

195. Transdifferentiation of cervical squamous cell carcinoma with ERBB2 amplification to adenocarcinoma: whole genome sequence analysis and successful control by anti-HER2 therapy.

196. Accuracy of a virtual PCI planner based on coronary CT angiography in calcific lesions.

197. Effect of backstroke ledge on backstroke start technique for water entry.

198. Fractional Flow Reserve-Guided Stent Optimisation in Focal and Diffuse Coronary Artery Disease.

199. A Study on Pharmacokinetics of Acetylsalicylic Acid Mini-Tablets in Healthy Adult Males-Comparison with the Powder Formulation.

200. Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial.

Catalog

Books, media, physical & digital resources